Metalloproteinase-mediated release of human Fas ligand.

Metalloproteinase-mediated release of human Fas ligand

Fas (APO-1, CD95) is a type I integral membrane protein initially identified by mAbs that induce apoptotic cell death upon binding to certain tumor cells and its belongs to the TNFR family. Fas is expressed on activated lymphocytes and in various tissues including the liver, lung, intestine, and skin. Molecular cloning of Fas ligand (FasL) revealed that it is a type II integral membrane protein...

Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.

Recent evidence suggests that one mechanism whereby cytotoxic drugs, such as doxorubicin, kill tumors is the induction or up-regulation of Fas ligand (FasL) expression on the tumor cell surface. The ensuing engagement of Fas by FasL on adjacent cells leads to apoptosis. However, despite cytotoxic drug-induced FasL expression, Fas-sensitive tumors frequently resist chemotherapy, suggesting that ...

Enhances the Cytotoxicity of Fas Ligand Inhibition of Metalloproteinase Cleavage

Metalloproteinase Shedding of Fas Ligand Regulates β-Amyloid Neurotoxicity

MMP-7, to release soluble FasL (sFasL), which deExtracellular deposits of -amyloid (A ) peptide closely creases the concentration of membrane-bound FasL match areas of neuronal loss in, and are a postmortem and has been reported to prevent apoptosis in some diagnostic indicator of, Alzheimer’s disease. Neuronal cancer cells [5]. Nagata and colleagues have shown that cultures treated with fibril...

Chronic neutropenia mediated by fas ligand.

Chronic neutropenia, often associated with rheumatoid arthritis, is a characteristic finding in large granular lymphocyte (LGL) leukemia. The mechanism of neutropenia is not known. Normal neutrophil survival is regulated by the Fas-Fas ligand apoptotic system. We hypothesized that neutropenia in LGL leukemia is mediated by dysregulated expression of Fas ligand. Levels of Fas ligand in serum sam...